CYTOKINETICS, INCORPORATED Income (Loss) from Continuing Operations before Income Taxes, Domestic
CYTOKINETICS, INCORPORATED (CYTK) reported Income (Loss) from Continuing Operations before Income Taxes, Domestic of -$106.29 million for the 12-month period ending 2018-12-31, per its 10-K filed 2019-03-07.
Discontinued › Income Statement › Pre-tax Income
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic · last filed 2019-03-07
- CYTOKINETICS, INCORPORATED income (loss) from continuing operations before income taxes, domestic for fiscal 2018 was -$106.29M.
- CYTOKINETICS, INCORPORATED income (loss) from continuing operations before income taxes, domestic for fiscal 2017 was -$127.23M, a 873.32% decline from fiscal 2016.
- CYTOKINETICS, INCORPORATED income (loss) from continuing operations before income taxes, domestic for fiscal 2016 was $16.45M.
- CYTOKINETICS, INCORPORATED income (loss) from continuing operations before income taxes, domestic for fiscal 2015 was -$37.50M.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month |
|---|---|
| 2018-12-31 | -$106.29M 10-K · filed 2019-03-07 |
| 2017-12-31 | -$127.23M 10-K · filed 2019-03-07 |
| 2016-12-31 | $16.45M 10-K · filed 2018-03-05 |
| 2015-12-31 | -$37.50M 10-K · filed 2018-03-05 |
| 2014-12-31 | -$14.65M 10-K · filed 2017-03-06 |
| 2013-12-31 | -$33.72M 10-K · filed 2016-03-03 |
| 2012-12-31 | -$40.37M 10-K · filed 2015-03-06 |
| 2011-12-31 | -$47.86M 10-K · filed 2014-03-07 |
| 2010-12-31 | -$49.46M 10-K · filed 2013-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 |